Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 7 Triple Negative Breast Neoplasms 2 Solid Tumors 1 Ovarian Neoplasms 1 Neoplasm, Residual 1 Neoplasm Metastasis 1 Metastatic Castration-Resistant Prostate Cancer 1 Hereditary Sensory and Autonomic Neuropathies 1 HER2-positive Breast Cancer 1 Endometrial Neoplasms 1 Colorectal Neoplasms 1 Advanced Unresectable or Metastatic Solid Malignancy 1

Interventions

Paclitaxel 134 Carboplatin 129 Bevacizumab 86 Gemcitabine 45 pembrolizumab 37 olaparib 33 Cisplatin 30 liposomal doxorubicin 29 Docetaxel 29 Cyclophosphamide 29 Topotecan 28 niraparib 27 Taxes 20 Etoposide 18 Filgrastim 16 Doxorubicin 16 Immunoglobulin G 15 Disulfides 15 apatinib 12 Letrozole 12 Albumin-Bound Paclitaxel 12 Drug Therapy 11 fluzoparib 10 fludarabine 10 Specimen Handling 10 Magnetic Resonance Spectroscopy 10 Biopsy 10 durvalumab 9 Nivolumab 9 pazopanib 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Ovarian Neoplasms × inavolisib × Clear all

NCT04931342 2026-03-10

BOUQUET

Hoffmann-La Roche

Phase 2 Active not recruiting

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡